[Preclinical and clinical studies of the efficacy of Panavir in therapy for tick-borne encephalitis].
The antiviral activity of Panavir was studied on a model of mice infected with the strain Sofjin of tick-borne encephalitis (TBE) virus. The efficacy of Panavir was studied in the treatment of the chronic (monotherapy; 30 patients) and acute febrile and meningeal (combined therapy; n = 113) forms of TBE. Panavir was found to have a positive effect on the clinical course of TBE and the immune mechanisms of the body's protection.
Litvin
A A
AA
Ratnikova
L I
LI
Deriabin
P G
PG
D000328:Adult; D000368:Aged; D000818:Animals; D000831:Animals, Newborn; D000914:Antibodies, Viral / Q000097:blood; D000941:Antigens / Q000097:blood; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004675:Encephalitis, Tick-Borne / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D051379:Mice; D008875:Middle Aged; D011341:Probucol / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000914:Antibodies, Viral; D000941:Antigens; D000975:Antioxidants; D011341:Probucol